Researchers have identified two compounds, K102 and K110, that could repair the nerve damage from multiple sclerosis. These drugs help regenerate the protective myelin sheath and balance immune responses. Licensed by Cadenza Bio, the discovery represents a leap from lab research to potential clinical therapy. If successful, it could transform how neurodegenerative diseases are treated.